Posts

Ignoring China's Biotech Industry Is No Longer an Option: Recent Developments and Implications

on

ImmuneOnco and Instil Bio's PD-L1xVEGF Bispecific Antibody Shows Promising Results in Phase 2 Lung Cancer Trial

on

Lilly's Mounjaro Matches Cardiovascular Benefit of Trulicity in Landmark Trial, Paving Way for Expanded Approval

on

Moderna to Cut 10% of Workforce in $1.5B Cost-Saving Push

on

AbbVie Raises 2025 Guidance and Eyes Strategic Deals in Neuroscience, Obesity, and Oncology

on

FDA Seeks Greater Alignment Between CBER and CDER: Makary Informs Industry Leaders

on

Merck Terminates Midstage Asset from $1.9B Pandion Acquisition over Lack of Clinical Benefit

on

Clinical Roundup: Cardiff, VYNE and NewAmsterdam Report Key Trial Results in Multiple Disease Areas

on

Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market

on

Teva Execs Shrug Off Pharmaceutical Tariff Threat as Turnaround Strategy Rolls Forward

on

Madrigal Pharmaceuticals Inks up to $2B Deal with CSPC for Preclinical Oral GLP-1, Plans Combination with Rezdiffra for MASH

on

Vinay Prasad Departs FDA Amid Conservative Criticism and Sarepta Gene Therapy Controversy

on

FDA Misses IND Deadline for Coya's ALS Asset, Citing Resource Constraints

on

Jaypirca Demonstrates Superior Efficacy Over Imbruvica in BTK Inhibitor Clash for CLL/SLL

on

Novo Nordisk Appoints New CEO and Reduces 2025 Sales Guidance

on

ARTBIO Raises $132M Series B to Advance Alpha Radiotherapy Pipeline and Manufacturing with Pb212

on

Bausch Health to Acquire DURECT and Breakthrough Liver Disease Candidate Larsucosterol for $63M Upfront

on

AstraZeneca Beats Q2 Estimates on Strong Cancer Drug Sales

on

Merck & Co. Targets $3B in Cost Savings Through Restructuring, Including Job Cuts

on

Novo Nordisk Names Insider Maziar Mike Doustdar as New CEO Amid Growth Challenges

on

Bristol Myers Squibb Spins Out Five Immunology Assets into New $300M Biotech with Bain Capital

on

Merck Announces $3 Billion Cost-Cutting and Restructuring Plan

on

FDA Reverses Course, Allows Sarepta to Resume Duchenne Gene Therapy Shipments

on

Trump's Pharmaceutical Tariffs Materialize in New US-EU Trade Deal

on

Adaptimmune Expects To Cut 62% of Staff After Cell Therapy Asset Sale

on

Apellis' Empaveli Gains FDA Approval for Broad C3 Glomerulopathy Use, Setting Up Competition with Novartis' Fabhalta

on

DTC vs. DTP: Regulatory Uncertainty & Access Challenges Drive New Go-to-Market Models (2025 Update)

on

GSK Strengthens COPD Offering via $12 Billion Multi-Program Deal with China's Hengrui Pharma

on

RFK Jr. Reportedly Weighs Preventive Services Panel Revamp, Raising Risks for HIV PrEP Drugmakers

on

FDA Investigates Elevidys Death; Sarepta and Roche Deny Link to Gene Therapy

on

Atai's Schizophrenia Drug Fails to Improve Cognition in Phase 2 Study

on

Rethinking Clinical Trial Data in the Era of Decentralization: Key Trends and Challenges (2025)

on

Roche Doubles Down on Alzheimer's with Next-Gen Amyloid-Lowering Drug Trontinemab

on

CHMP Recommends Against Approval of Elevidys Gene Therapy in Europe, Dealing Blow to Sarepta and Roche

on

Trinity Biotech Repositions for AI-Driven Growth with CGM+ Biosensor Platform

on

FDA Official Says Sarepta Faces Major Hurdles to Reintroduce DMD Therapy Elevidys

on

Galapagos Considers Sale of Cell Therapy Unit in Ongoing Strategic Overhaul

on

Rocket Pharmaceuticals Cuts 30% of Staff, Refocuses on Heart Gene Therapies

on

Novartis Bets on Covalent Chemistry in $1B Matchpoint Therapeutics Deal

on

AstraZeneca's Self-Administered Myasthenia Gravis Drug Gefurulimab Clears Phase 3 Trial

on

RFK Jr. Approves ACIP Recommendation to Remove Thimerosal from U.S. Flu Vaccines

on

LEO Pharma Scores FDA Approval for Anzupgo as First Treatment for Chronic Hand Eczema

on

FDA Delays Blenrep Decision, Challenging GSK's Multiple Myeloma Comeback Plans

on